Latest Varenicline Stories
Combining two smoking cessation therapies is more effective than using just one for male and highly nicotine-dependent smokers who weren't initially helped by the nicotine patch.
Transparency Market Research published a new report "Smoking Cessation and Nicotine De-addiction Products Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 -
ALBANY, New York, April 17, 2014 /PRNewswire/ -- MRRBIZ includes new market research report "Smoking Cessation and Nicotine De-Addiction Products Market (Nicotine Gums,
ResearchMoz.us include new market research report "OpportunityAnalyzer Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update" to its
ALBANY, New York, March 25, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Smoking Cessation and Nicotine De-addiction
Among cigarette smokers, combining the smoking cessation medications varenicline and bupropion, compared with varenicline alone, resulted in higher smoking abstinence rates for one outcome but not the other at three and six months; rates were similar at one year.
Among cigarette smokers, the combined use of the smoking cessation medications varenicline and bupropion, compared with varenicline alone, resulted in better rates of smoking abstinence at 12 weeks, but rates were similar after one year.
Extended treatment with the smoking cessation drug varenicline (Chantix) significantly improved the ability of individuals with serious mental illness to maintain abstinence from tobacco after a standard 12-week course of treatment.
Three major types of smoking cessation therapies don't increase the risk of heart attack, stroke or heart-related death.